AcelRx Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Talphera

28/03/2023 21:09

* AcelRx Pharmaceuticals Inc  ACRX.OQ   ACRX.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 30. 
    * The Hayward California-based  company is expected to
report  a
224,900.0% increase in revenue to $4.5 million from $2 thousand
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for AcelRx
Pharmaceuticals
Inc is for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AcelRx
Pharmaceuticals Inc is $80​, above​ its last closing price
of $0.76. ​​​

This summary was machine generated March 28 at 20:09 GMT.  All
figures in US dollars  unless otherwise stated